Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to kill cancer cells or stop them from growing. Monoclonal antibodies, such as
rituximab and alemtuzumab, can block cancer growth in different ways. Some find cancer cells
and help kill them or carry cancer-killing substances to them. Others interfere with the
ability of cancer cells to grow and spread. It is not yet known whether giving fludarabine
and cyclophosphamide together with rituximab is more effective than giving fludarabine and
cyclophosphamide together with alemtuzumab in treating B-cell chronic lymphocytic leukemia.
PURPOSE: This randomized phase III trial is studying giving fludarabine together with
cyclophosphamide and rituximab to see how well it works as first-line therapy compared with
giving fludarabine together with cyclophosphamide and alemtuzumab in treating patients with
B-cell chronic lymphocytic leukemia.